SENSEX NIFTY

Fda

Feb 17, 2017 at 15:29 | Source: Moneycontrol.com
Biocon shares gained 2.6 percent to hit a record high of Rs 1,123 after the US health regulator USFDA has accepted pharma major Mylan's biologics licence application (BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim.
Feb 17, 2017 at 15:22 | Source: CNBC-TV18
Market in yesterdays trade rallied owing to the gains from healthcare stocks. Swati Kulkarni of UTI MF said that pharma companies are going through the remediation process and after they US FDA approvals, the pharma stocks will perform well.
Feb 17, 2017 at 14:50 | Source: PTI
US health regulator USFDA hasaccepted pharma major Mylan's biologics licence application(BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim,Biocon and Mylan have said.
Feb 17, 2017 at 10:30 | Source: Moneycontrol.com
Brokerage firms and analysts tracking the stock welcomed the development and most have raised the target price. To be sure a lot of them were expecting resolution of the warning letter on Moraiya facility in the fourth quarter of FY17.
Feb 15, 2017 at 14:40 | Source: PTI
According to a notification issued by the US Food and Drug Authority, Dr Reddy's is recalling Olanzapine tablets USP of 2.5 mg while Aurobindo is recalling Pantoprazole Sodium for Injection, 40mg per vial from the market.
Feb 14, 2017 at 15:36 | Source: CNBC-TV18
During his campaign, US president Donald Trump vowed to ease the burden of the healthcare industry in US by reducing taxes and government regulations. Two important decisions expected from the Trump administration is appointment of Food and Drug Administration (FDA) commissioner and drug price control.
Feb 10, 2017 at 09:50 | Source: PTI
"This is to inform that our Paithan facility was recently inspected by the US FDA and we are issued one procedural related 483," Ajanta Pharma said in a BSE filing.
Feb 09, 2017 at 22:00 | Source: Moneycontrol.com
Laurus Laboratories posted a 17.5 percent increase in net profit to Rs 47.2 crore in the third quarter ended December on account of larger uptake of its API business.
Feb 09, 2017 at 20:17 | Source: Moneycontrol.com
The company said it plans to mitigate the any loss in revenue from Glumetza and Fortamet with over 25 potential launches in the next 12 months - including some big ones such as as birth-control pill Minastrin 24, HIV drug Epzicom, hepatitis-B medication viread, among others.
Feb 09, 2017 at 10:49 | Source: Moneycontrol.com
Ajanta Pharma Ltd has informed BSE that the Company's Paithan facility was recently inspected by US FDA and the Company has issued one procedural related 483. The Company is in process of responding to the same within the stipulated time prescribed by US FDA.
Messages on Fda »

mardiarahul

New Member

0 Follower

Sun Pharma  

us fda approval it comes, it goes up till 850/- - my target for sun pharma is rs 850 for the short term with a stoploss of rs 640

3.04 PM Feb 17th

cpmc

Silver Member

42 Followers

Natco Pharma  

Just to add, they also shared on the call that there could be new entrants coming in for gTamiflu upon patent expiry (Feb 23rd, 2017). Personally speaking, my guess is that potential entrants in the FDA approval queue should have ideally received a Tentative Approval atleast by now (given we are 1

3.01 PM Feb 17th

raklaw

Gold Member

448 Followers

Vista Pharma  

One of the oldest fda approved plants in this co

2.05 PM Feb 17th

new_era87

New Member

3 Followers

Divis Labs  

any idea when the fda observation for form 483 is coming out? this share can go 20% up or down anytime after this news..

11.48 AM Feb 17th

News Flash

Platinum Member

1373 Followers

Just Posted  

Top Stories On IBH : Cadila Healthcare's Moraiya Unit Gets No Observations From US FDA

10.00 PM Feb 16th

News Flash

Platinum Member

1373 Followers

Just Posted  

Top Stories On IBH : Cadila Healthcare's Moraiya Unit Gets No Observations From US FDA

9.45 PM Feb 16th

News Flash

Platinum Member

1373 Followers

Just Posted  

Top Stories On IBH : Cadila Healthcare's Moraiya Unit Gets No Observations From US FDA

9.30 PM Feb 16th

News Flash

Platinum Member

1373 Followers

Just Posted  

Top Stories On IBH : Cadila Healthcare's Moraiya Unit Gets No Observations From US FDA

9.15 PM Feb 16th

News Flash

Platinum Member

1373 Followers

Just Posted  

Top Stories At This Hour : Cadila Healthcare's Moraiya Unit Gets No Observations From US FDA

8.15 PM Feb 16th

andyin

New Member

6 Followers

Biocon  

In Sept 2017 it will be Trastuzumab with FDA. May/June is 2017 is expected for EMA review to complete for both molecules and glargine in Sept/oct 2017

8.13 PM Feb 16th

News across the web »
Aug 26, 2016 at 18:38 | Source: FirstPost
Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.